Publications (5)4.69 Total impact
-
Article: Therapeutic plasma-exchange in hematologic disease: Results from a single center in Eastern Anatolia.
[show abstract] [hide abstract]
ABSTRACT: Therapeutic plasma-exchange (TPE) is used as primary and adjunctive therapy in treatment of several hematologic diseases. We retrospectively evaluated the results of TPE in hematologic diseases during 2008-2012. A total of 301 TPE procedures were performed in 44 patients (19 male and 25 female, with mean age of 50.6±15years). Fifteen of 44 patients had thrombotic thrombocytopenic purpura (TTP), 14 patients had HELLP syndrome (Hemolysis Elevated Liver enzymes, Low Platelet count), 10 patients had multiple myeloma-hyperviscosity and the rest five patients had snake bite. Fresh frozen plasma (FFP) was used as replacement fluid. Complete response (CR) was achieved on 13 patients (87%) in primarily TTP. CR was achieved in all other three diseases. Total complications were detected in 8.1% of the TPE procedures. Adverse events (AEs), were seen in 5.4% of all procedures. None of the patients died from any complication. AE occurred in 4% (Grade-I), 1% (Grade-II), and 0.3% (Grade-III) of the procedures. The most common AE were nausea/vomiting, hypotension, pruritus and abdominal pain. TPE is effectively and safely carried out in our center in hematologic diseases.Transfusion and Apheresis Science 04/2013; · 1.25 Impact Factor -
Article: Thrombocytopenia in Adults: Review Article
[show abstract] [hide abstract]
ABSTRACT: Thrombocytopenia is the result of falling the number of platelet from 150,000/microL. There are three main reasons of thrombocy-topenia, a-Decreasing of making platelet b-Increasing of destruc-tion platelet c-Changing of distribution platelet. Pseudothrombo-cytopenia must be kept in mind too. Both hereditary and acquired reasons help thrombocytopenia have wide spreaded, but acquired causes are more common with increasing age. Thrombocytopenia separates three stages as numerical. Mild: 100,000 -150,000/mi-croL, Moderate: 50,000 -100,000/microL. Severe: < 50,000/mi-croL. However, thrombocytopenia is not usually detected clinically until the platelet count has fallen to levels below 100,000/microL. Severe thrombocytopenia, such as intracerebral and intra-abdomi-nal bleeding may be life threatening. So diagnosing the treatment immediately can save the life. Transfusion of platelet may not need in all thrombocytopenias. Treatment of the underlying disease may be sufficient. The reason of thrombocytopenia can be temporary but also can be caused severe diseases. Causes of thrombocytopenia change development levels of countries, according to geographical distribution and application centers. In this review we emphasize common etiologies seen in adult patients with thrombocytopenia.Journal of Hematology. 06/2012; 1(2-3):44-53. -
Article: Thrombocytopenia in Adults: Review Article
[show abstract] [hide abstract]
ABSTRACT: Thrombocytopenia is the result of falling the number of platelet from 150,000/microL. There are three main reasons of thrombocy-topenia, a-Decreasing of making platelet b-Increasing of destruc-tion platelet c-Changing of distribution platelet. Pseudothrombo-cytopenia must be kept in mind too. Both hereditary and acquired reasons help thrombocytopenia have wide spreaded, but acquired causes are more common with increasing age. Thrombocytopenia separates three stages as numerical. Mild: 100,000 -150,000/mi-croL, Moderate: 50,000 -100,000/microL. Severe: < 50,000/mi-croL. However, thrombocytopenia is not usually detected clinically until the platelet count has fallen to levels below 100,000/microL. Severe thrombocytopenia, such as intracerebral and intra-abdomi-nal bleeding may be life threatening. So diagnosing the treatment immediately can save the life. Transfusion of platelet may not need in all thrombocytopenias. Treatment of the underlying disease may be sufficient. The reason of thrombocytopenia can be temporary but also can be caused severe diseases. Causes of thrombocytopenia change development levels of countries, according to geographical distribution and application centers. In this review we emphasize common etiologies seen in adult patients with thrombocytopenia.J Hematol. 01/2012; 1(2-3):44-53. -
Article: Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
[show abstract] [hide abstract]
ABSTRACT: Despite new therapeutic options and treatment strategies, anemia still remains one of the major complications of chronic kidney disease (CKD), especially in patients undergoing chronic hemodialysis for end-stage renal disease. Successful management of anemia is a central part of patient care that may improve clinical outcomes. Although the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) working group reformulated its recommendations by stating that the hemoglobin target in patients receiving erythropoiesis stimulatory agents (ESA) should generally be 11-12 g/dl, this target value can not be achieved in many of them, despite treatment with high doses of ESA. The aim of the present review is to provide an update of the recent literature on causes and possible management of ESA-resistant anemia in CKD patients.Blood Purification 10/2009; 29(1):1-12. · 2.10 Impact Factor -
Article: In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfarin.
[show abstract] [hide abstract]
ABSTRACT: Ankaferd comprises a mixture of Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum and Urtica dioica. Ankaferd Blood Stopper (ABS) has been approved in the management of bleedings. This study aimed to evaluate in vivo hemostatic effect of ABS in rats pretreated with warfarin. Wistar rats (210-270 g) were treated either with warfarin (2 mg/kg) or vehicle (0.9% NaCl) orally before bilateral hind leg amputation. ABS was administered topically to one of the amputed legs. The duration of bleeding and the amount of bleeding were measured to evaluate the hemostatic effect of ABS. Topical ABS administration to amputed leg shortened the duration of bleeding markedly in both untreated and warfarin-treated rats by 31.9% [1.42 min (95% CI: 0.35-2.49)] and 43.5% [5.12 min (95% CI: 2.16-8.07)] respectively. The amount of bleeding in ABS-administered amputed leg showed a decrease by 53.8% in warfarin-treated group. ABS has in vivo hemostatic actions that may provide a therapeutic potential for the management of patients with deficient primary hemostasis in clinical medicine.Clinical and Applied Thrombosis/Hemostasis 01/2009; 15(3):270-6. · 1.33 Impact Factor
